Skip to main content
. Author manuscript; available in PMC: 2026 Jan 1.
Published in final edited form as: Oral Oncol. 2024 Dec 6;160:107126. doi: 10.1016/j.oraloncology.2024.107126

Figure 2:

Figure 2:

A) Flow cytometry gating strategy of T cell from single cell suspensions derived from tumors of mice treated with CPSI-1306 or vehicle control. Gating for CD4+ and CD8+ cells was performed on CD45+ CD3+ cells. B) Representative flow cytometry plot for CD4+ and CD8+ T cells in MOC2 tumors of mice treated with vehicle control and CPSI-1306. C) Graphical representation of CD4+ and CD8+ T cell subsets expressed as a percentage of CD45+ cells and total live cells in MOC2 tumors of CPSI-1306 and vehicle control treated groups. D) Representative flow cytometry plot for CD4+ and CD8+ T cells in MOC1 tumors of mice treated with vehicle control and CPSI-1306. (E) Graphical representation of CD4+ and CD8+ T cell subsets expressed as a percentage of CD45+ cells and total live cells in MOC1 tumors of CPSI-1306 and vehicle control treated groups. (F) Gene expression profile of chemokines Ccl5, Cxcl9, Cxcl10, Cxcl11, and Ccl21 in tumors obtained from tumor bearing mice treated with CPSI-1306 or vehicle control, normalized to β-actin. * p value < 0.05, ** p value < 0.01